Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 50Lymphoma, Non-Hodgkin 36Lymphoma, Large B-Cell, Diffuse 29Lymphoma 29Lymphoma, Mantle-Cell 26Lymphoma, B-Cell, Marginal Zone 22Lymphoma, B-Cell 18Recurrence 13Neoplasms 11Leukemia 7Leukemia, B-Cell 6Burkitt Lymphoma 5Leukemia, Hairy Cell 4Waldenstrom Macroglobulinemia 3Neoplasm, Residual 3Melanoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Disease 2Dendritic Cell Sarcoma, Interdigitating 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1

Interventions

ibrutinib 8fludarabine 8fludarabine phosphate 7Cyclophosphamide 7Busulfan 6blinatumomab 5Rituximab 5Whole-Body Irradiation 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Methotrexate 3Mesna 3Lenalidomide 3Bone Marrow Transplantation 3Bendamustine Hydrochloride 3thymoglobulin 2pirtobrutinib 2Vincristine 2Patient Reported Outcome Measures 2Doxorubicin 2Biopsy 2Behavior Therapy 2Alemtuzumab 2venetoclax 1tozasertib 1sargramostim 1romiplostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphoid × obinutuzumab × Clear all
NCT01680991 2016-04-25

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Hoffmann-La Roche

Phase 1 Completed
48 enrolled 27 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡